115913-75-2

Upstream product

• 2096-10-8 adenosine-2-amine 
• 121231-93-4 2,6-diamino-9-(<2'-O-(p-tosyl)sulfonyl>-β-D-ribofuranosyl)purine 
• 115913-81-0 N²-acetyl-2'-O-tosyl-2,6-diamino-9-β-D-ribofuranosylpurine 
• 69370-84-9 2'-O-tosylguanosine 
• 118-00-3 G 
• 93-97-0 benzoic acid anhydride 
• 116002-28-9 9-(2'-deoxy-β-D-threo-pentofuranosyl)guanine 

Downstream Products

• 115913-82-1 5'-O-benzoyl-3'-fluoro-2',3'-dideoxyguanosine 
• 92562-88-4 9-(2,3-dideoxy-3-fluoro-β-D-erythro-pentofuranosyl)guanine 
• 115913-77-4 5'-O-benzoyl-3'-azido-2',3'-dideoxyguanosine 
• 115913-76-3 N²-<(dimethylamino)methylene>-5'-O-benzoyl-3'-azido-2',3'-dideoxyguanosine 

Relevant academic research and scientific papers

Synthesis and anti-HIV activity of different sugar-modified pyrimidine and purine nucleosides

A series of base-modified pyrimidine 3'-azido-2',3'-dideoxynucleosides and 3'-substituted purine and pyrimidine 2',3'-dideoxynucleosides have been synthesized and evaluated for their inhibitory activity against human immunodeficiency virus (HIV) replication in MT-4 cells. The following pyrimidine derivatives emerged as the most potent and/or selective inhibitors of HIV-induced cytopathogenicity (in order of decreasing selectivity: 3'-azido-3'-deoxythymidine (AZT), 3'-azido-2',3'-dideoxyuridine (AzddUrd), 3'-azido-2',3'-dideoxy-5-methylcytidine (AzddMeCyd), 3'-fluoro-ddUrd (FddUrd), 3'-fluoro-ddThd (FddThd), the N4-hydroxylated derivative of AzddMeCyd and the N4-methylated derivative of AzddMeCyd. Among the purine 2',3'-dideoxynucleosides, 3'-azido-2',3'-dideoxyguanosine (AzddGuo), 3'-fluoro-ddGuo (FddGuo), and 3'-fluoro-2,6-diaminopurine 2',3'-dideoxynucleoside (FddDAPR) were the most selective inhibitors of HIV replication.